Autres langues H. Lundbeck A/S

Actions

HLUN B

DK0061804770

Produits pharmaceutiques

Marché Fermé - Nasdaq Copenhagen Autres places de cotation 17:20:00 19/05/2026			Varia. 5j.	Varia. 1 janv.
40,16 ^DKK	+0,05%		-3,37%	-6,95%

18/05	Lundbeck : le statut de médicament orphelin accordé à l'asedebart au Japon	MT
18/05	Lundbeck obtient le statut de médicament orphelin au Japon pour l'asedebart	FW

Autres langues

12:39	H Lundbeck A/S : Transcript (Transcript)
18/05	Lundbeck's Asedebart Secures Orphan Drug Designation in Japan
18/05	Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease
13/05	H LUNDBECK : Strong Q1, but long-term growth uncertainty hovers over valuation
13/05	H Lundbeck A/S : Investor Presentation (Lundbeck InvestorDeck Q1 2026 FINAL)
12/05	H. Lundbeck A/S Raises Earning Guidance for Full Year of 2026
12/05	H. Lundbeck A/S Reports Earnings Results for the First Quarter Ended March 31, 2026
12/05	H Lundbeck A/S : Release (Q1 2026 Corporate Release)
12/05	Strong start to 2026: +21% CER revenue growth (+13% CER underlying)
12/05	Lundbeck raises financial guidance for 2026
19/04	Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)
19/04	H. Lundbeck A/S Presents New Data At AAN2026 Highlighting Real-World Changes in Migraine-Related Cognitive Symptoms After Starting VYEPTI® (Eptinezumab)
13/04	Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting
30/03	H Lundbeck A/S : Remuneration Policy 2026 (Remuneration Policy 2026)
23/03	H. Lundbeck Price Target Down as AlphaValue/Baader Europe Expects Patent Expirations to Weigh on Growth
20/03	H LUNDBECK : Markets need more proof of growth promise
18/03	H. Lundbeck A/S Announces Board and Board Committee Appointments
18/03	H. Lundbeck A/S Approves Dividend for the Accounting Year 2025
18/03	Lundbeck held its Annual General Meeting on 18 March 2026 at the company's registered office
18/03	H Lundbeck A/S : Presentation (AGM Presentation 2026)
16/03	H. Lundbeck A/S Advances Parkinson's Research With New Phase 1b Data On Lu AF28996 And Presents Updates On Multiple System Atrophy Programs
16/03	Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026
10/03	H. Lundbeck A/S Appoints Markus Kede as Senior Vice President and Chief AI Officer and Joins Executive Leadership Team, Effective July 1, 2026
10/03	H. Lundbeck Names Chief Artificial Intelligence Officer
10/03	Lundbeck appoints Chief AI Officer